Skip to main content
SpringerLink
Log in

Relapsed Acute Lymphoblastic Leukemia

  • Chapter
Acute Leukemias

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Treatment of acute lymphoblastic leukemia in children is one of the great success stories of combination chemotherapy. Unfortunately, adults fare much worse and the majority of adult patients ultimately fail their initial treatment program. Most current induction regimens obtain complete responses (CRs) in 65–90% of newly diagnosed adult patients with acute lymphoblastic leukemia (ALL). Early deaths account for some of the induction failures, but in most studies 10–25% of patients have disease resistant to vincristine/prednisone-based regimens. In addition to these primary refractory patients, 60–70% of patients who achieve a CR relapse. Treatment of relapsed and refractory patients is therefore an important and common problem. Numerous regimens have been reported in the setting of relapsed ALL. There are two widely tested approaches to reinduction therapy for adult patients with recurrent or refractory ALL. One option is to treat the patient with a regimen that is similar to their original induction therapy (this strategy is obviously not used for primary refractory patients).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Woodruff R, Lister T, Paxton A, Whitehouse J, Malpas J (1978) Combination chemotherapy for hematologic relapse in adult acute lymphoblastic leukemia (ALL). Am J Hematol 4:173–177

    Article  PubMed  CAS  Google Scholar 

  2. Capizzi RI, Poole M, Cooper MR, et al. (1984) Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694–700

    PubMed  CAS  Google Scholar 

  3. Amadori S, Papa F, Avisati G, et al. (1984) Sequential combination high-dose Ara-C and asparaginase for the treatment of advanced acute leukemia and lymphoma. Leuk Res 8:729–735

    Article  PubMed  CAS  Google Scholar 

  4. Wells RJ, Feusner J, Devney R, et al. (1985) Sequential high-dose cytosine arabinoside-asparaginase treatment in advance childhood leukemia. J Clin Oncol 3:998–1004

    PubMed  CAS  Google Scholar 

  5. Ishii E, Mara T, Ohkubo K, et al. (1986) Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin. Med Pediatr Oncol 14:73

    Article  PubMed  CAS  Google Scholar 

  6. Koller CA, Kantarjian HM, Thomas D, et al. (1997) The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11:2039–2044

    Article  PubMed  CAS  Google Scholar 

  7. Giona F, Testi A, Amadori G, et al. (1990) Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol 1:51–55

    PubMed  CAS  Google Scholar 

  8. Tan C, Steinherz P, Meyer P (1990) Idarubicin in combination with high-dose cytosine arabinoside in patients with acute leukemia in relapse. Proc Annu Meet Am Assoc Cancer Res 31:A1133 (abstr)

    Google Scholar 

  9. Hiddemann W, Kreutzman H, Straif K, et al. (1987) High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14:73

    PubMed  CAS  Google Scholar 

  10. Leclerc J, Rivard G, Blanch M, et al. (1988) The association of once a day high-dose Ara-C followed by mitoxantrone for 3 days induces a high rate of complete remission in children with poor prognosis acute leukemia. Blood 72(Suppl):210 (abstr)

    Google Scholar 

  11. Kantarjian H, Walters R, Keating M, et al. (1990) Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65:5–8

    Article  PubMed  CAS  Google Scholar 

  12. Feldman EJ, Alberts DS, Arlin Z, et al. (1993) Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11:2002–2009

    PubMed  CAS  Google Scholar 

  13. Weiss MA, Drullinsky P, Maslak P, et al. (1998) A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 12(6):865–868

    Article  PubMed  CAS  Google Scholar 

  14. Weiss MA, Aliff TB, Tallman MS, et al. (2002) A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 95(3):581–587

    Article  PubMed  CAS  Google Scholar 

  15. Davies SM, Ramsay NK, Weisdorf DJ (1996) Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 17:737–740

    PubMed  CAS  Google Scholar 

  16. Gale RP, Horowitz MM, Ash RC, et al. (1994) Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646–652

    PubMed  CAS  Google Scholar 

  17. Kolb H-J, Schattenberg A, Goldman JM, et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041

    PubMed  CAS  Google Scholar 

  18. Passweg JR, Tiberghien P, Cahn J-Y, et al. (1998) Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 21:153–158

    Article  PubMed  CAS  Google Scholar 

  19. Doney K, Fisher LD, Appelbaum FR, et al. (1991) Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 7:453–459

    PubMed  CAS  Google Scholar 

  20. Weisdorf DJ, Woods WG, Nesbit ME Jr, et al. (1994) Allogeneic bone marrow transplantation for acute lymphoblastic leukemia: Risk factors and clinical outcome. Br J Haematol 86:62–69

    PubMed  CAS  Google Scholar 

  21. Sebban C, Lepage E, Vernant J-P, et al. (1994) Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in first complete remission: A comparative study. J Clin Oncol 12:2580–2587

    PubMed  CAS  Google Scholar 

  22. Zhang M-J, Hoelzer D, Horowitz MM, et al. (1995) Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 123:428–431

    PubMed  CAS  Google Scholar 

  23. Attal M, Blaise D, Marit G, et al. (1995) Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplant. Blood 86:1619–1628

    PubMed  CAS  Google Scholar 

  24. Thiebaut A, Vernant JP, Degos L, et al. (2000) Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87 (Review). Hematol Oncol Clin N Amer 14:1353–1366

    Article  CAS  Google Scholar 

  25. Fiere D, Lepage E, Sebban C, et al. (1993) Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 11:1990–2001

    PubMed  CAS  Google Scholar 

  26. Barrett AJ, Horowitz, MM, Ash RC, et al. (1992) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79:3067–3070

    PubMed  CAS  Google Scholar 

  27. Dombret H, Gabert J, Boiron JM, et al. (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the prospective multicenter LALA-94 trial. Blood 100:2357–2366

    Article  PubMed  CAS  Google Scholar 

  28. Druker BJ, Talpaz M, Resta DJ, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    Article  PubMed  CAS  Google Scholar 

  29. Ottmann OG, Druker BJ, Sawyers CL, et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100: 1965–1971

    Article  PubMed  CAS  Google Scholar 

  30. Hoffman WK, Jones JC, Lemp NA, et al. (2002) Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860–1862

    Article  Google Scholar 

  31. Hoffman WK, Komor M, Wassman B, et al. (2003) Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102: 659–661

    Article  Google Scholar 

  32. Thomas DA, Faderl S, Cortes J, et al. (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396–4407

    Article  PubMed  CAS  Google Scholar 

  33. Wassmann B, Scheuring U, Pfeifer H, et al. (2003) Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia 17:1919–1924

    Article  PubMed  CAS  Google Scholar 

  34. Sanders KE, Ha CS, Cortes-Franco JE, et al. (2004) The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 100:2160–2180

    Article  Google Scholar 

  35. Kantarjian H, Gandhi V, Cortes J, et al. (2001) Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 103:2379

    Google Scholar 

  36. Gandhi V, Plunkett W, Rodriguez CO Jr, et al. (1998) Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16:3607–3615

    PubMed  CAS  Google Scholar 

  37. Gandhi V, Plunkett W, Weller S, et al. (2001) Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19(8):2142–2152

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Nicole Lamanna, Melissa von Hassel & Mark Weiss

Authors
  1. Nicole Lamanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa von Hassel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Lamanna, N., von Hassel, M., Weiss, M. (2008). Relapsed Acute Lymphoblastic Leukemia. In: Acute Leukemias. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72304-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72304-2_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72302-8

  • Online ISBN: 978-3-540-72304-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation